Quest Diagnostics Inc vs Uber Technologies Inc — how do they compare? Quest Diagnostics Inc trades at $204.95 (market cap $22.80B), while Uber Technologies Inc trades at $72.61 (market cap $146.73B). The key difference: Uber Technologies Inc is far larger — about 6.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| DGX | UBER | |
|---|---|---|
Market Cap | $22.80B | $146.73B |
Sector | Health | Industrials |
52-Week High | $216.02 | $100.10 |
52-Week Low | $166.42 | $68.61 |
Enterprise Value | $28.82B | $153.05B |
Dividend Yield | 1.67% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Uber Technologies (UBER) trades at $74.26, down 0.38% on the day, with strong analyst consensus of 49 buys and 0 sells. The stock shows bullish technical signals with moving averages supporting upward momentum. Fundamentally, Uber demonstrates robust revenue growth from $31.9B in 2022 to $52.0B in 2025, though net income margin has moderated from 22.41% to 19.32%. Recent developments include strategic moves into autonomous vehicles with partnerships in Spain and Germany.
Uber presents a compelling growth story with expanding profitability and dominant market position. The 36% upside to consensus price target of $108.92 suggests significant potential. Key risks include execution challenges in autonomous vehicle rollout, competitive pressures in key markets like India, and potential margin compression. Operating cash flow strength at $10.1B supports continued investment in growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →